2,120 results match your criteria Lymphoma Diffuse Mixed

Presence of a mouse mammary tumour virus-like in feline lymphomas: a preliminary study.

Infect Agent Cancer 2022 Jun 23;17(1):35. Epub 2022 Jun 23.

Dipartimento di Scienze Veterinarie, Università di Pisa, Viale delle Piagge, 2, 56124, Pisa, Italy.

The mouse mammary tumour virus (MMTV) is implicated in the aetiology of murine mammary carcinomas and a variant of it, the type B leukemogenic virus, can cause murine thymic lymphomas. Interestingly, a MMTV-like virus is suspected to be involved in human breast cancer and feline mammary carcinomas. However, to date, no cases of MMTV-like sequence amplifications have been described in lymphoid neoplasms in veterinary literature. Read More

View Article and Full-Text PDF

Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018).

Am J Hematol 2022 Jun 17. Epub 2022 Jun 17.

Department of Haematology and Medical Oncology, Mayo Clinic Jacksonville, Florida.

Intravascular lymphoma (IVL) is a rare extranodal non-Hodgkin lymphoma. We performed a retrospective analysis of 55 IVL patients who were treated at our institution 2003-2018. Median age at diagnosis was 68 years, and 64% were males. Read More

View Article and Full-Text PDF

Multimodal Sonographic Appearance and Survival Outcomes of 69 Cases of Primary Thyroid Lymphoma Over 10 Years.

J Ultrasound Med 2022 Jun 8. Epub 2022 Jun 8.

Department of Ultrasound Medicine, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy Of Sciences, Hangzhou, China.

Objectives: To investigate ultrasound appearance and the survival outcomes for patients with primary thyroid lymphoma (PTL).

Methods: Ultrasonic images and clinical characteristics from pathologically confirmed 69 PTL patients (2008-2019) were retrospectively analyzed. The clinical characteristics, ultrasonic characters, and prognostic factors were analyzed. Read More

View Article and Full-Text PDF

Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors.

Psychooncology 2022 Jun 7. Epub 2022 Jun 7.

School of Nursing & Midwifery, Faculty of Health Sciences, Trinity College Dublin, Dublin, Ireland, D02 T283.

Objective: to establish an understanding of the unmet needs of people living with or beyond a lymphoma diagnosis. Survivors of lymphoma are at increased risk of unmet needs due to cancer, treatment-related toxicities and extended survivorship. Despite the rapidly growing numbers of lymphoma survivors, their needs and research priorities are underserved and undervalued, therefore left largely unaddressed. Read More

View Article and Full-Text PDF

[Application of anti-programmed cell death protein 1 antibody in children with refractory or relapsed Hodgkin lymphoma].

Zhonghua Er Ke Za Zhi 2022 Jun;60(6):573-577

Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

To explore the efficacy of anti-programmed cell death protein 1 (PD-1) antibody for children with refractory or relapsed Hodgkin lymphoma. Clinical data including short-term efficacy, long-term efficacy and adverse reaction of Hodgkin lymphoma children treated with anti-PD-1 antibody in Beijing Children's Hospital, Capital Medical University from December 2017 to June 2021 were analyzed retrospectively. Efficacy was evaluated as complete remission (CR), partial remission (PR), stable disease (SD), progressed disease (PD) and no response. Read More

View Article and Full-Text PDF

Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering.

Cancers (Basel) 2022 May 13;14(10). Epub 2022 May 13.

Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Identifying the progression of chronic lymphocytic leukemia (CLL) to accelerated CLL (aCLL) or transformation to diffuse large B-cell lymphoma (Richter transformation; RT) has significant clinical implications as it prompts a major change in patient management. However, the differentiation between these disease phases may be challenging in routine practice. Unsupervised learning has gained increased attention because of its substantial potential in data intrinsic pattern discovery. Read More

View Article and Full-Text PDF

Rare Case of Mixed Phenotype Acute Leukemia Presenting as a Myeloid Sarcoma Without Leukemic Involvement.

Perm J 2022 Apr 5;26(1):132-136. Epub 2022 Apr 5.

Department of Oncology/Hematology, Kaiser Permanente Santa Clara, Santa Clara, CA, USA.

Introduction: Mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia with immunophenotypic features of both myeloid-derived and lymphoid-derived lineages.

Case Presentation: We present an atypical case of a 32-year-old woman presenting with an anterior mediastinal mass and pericardial/pleural involvement that was initially diagnosed as primary mediastinal diffuse large B-cell lymphoma. However, flow cytometry on pleural fluid confirmed the diagnosis of MPAL of B-cell/myeloid lineage without peripheral blood/bone marrow involvement. Read More

View Article and Full-Text PDF

A rare case of synchronous multiple primary malignancies of breast cancer and diffuse large B-cell lymphoma that responded to multidisciplinary treatment: a case report.

Surg Case Rep 2022 May 19;8(1):99. Epub 2022 May 19.

Department of Surgery, Miyazaki Prefectural Miyazaki Hospital, 5-30 Kitatakamatsu, Miyazaki, Miyazaki, 880-8510, Japan.

Background: Multiple primary malignancies of breast cancer and diffuse large B-cell lymphoma (DLBCL) are rare. Here, we report a case of advanced breast cancer and DLBCL managed with multidisciplinary therapy preceded by surgery with a successful outcome.

Case Presentation: During a medical examination, a 71-year-old woman was diagnosed with a right breast mass, enlarged lymph nodes throughout the body, and a splenic tumor. Read More

View Article and Full-Text PDF

Smooth Versus Textured Tissue Expander Breast Reconstruction: Complications and Efficacy.

Ann Plast Surg 2022 05;88(3 Suppl 3):S288-S292

From the Division of Plastic and Reconstructive Surgery, Department of Surgery, The Pennsylvania State University.

Introduction: Ongoing recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and its link with textured devices has brought a paradigm shift in prosthetic-based breast reconstruction. Many institutions no longer offer textured expansion devices for staged reconstruction. However, there is a paucity of data regarding the efficacy of smooth tissue expanders (TE). Read More

View Article and Full-Text PDF

A Case of Tofacitinib-Induced Lymphomatoid Papulosis With Ocular Involvement.

Am J Dermatopathol 2022 Jul 4;44(7):523-525. Epub 2022 May 4.

Department of Dermatology, Oregon Health and Science University, Portland, OR.

Abstract: Janus kinase (JAK) inhibitors are being prescribed with increasing regularity in dermatology. We report on a patient who initiated treatment with tofacitinib for refractory erythema elevatum diutinum and subsequently developed a novel cutaneous outbreak characterized by firm violaceous papules on the trunk and extremities along with conjunctival injection and periorbital inflammation. Biopsy of affected tissue from both the cutaneous and ophthalmologic sources demonstrated increased numbers of CD30+ large atypical cells amid a mixed inflammatory cell infiltrate, consistent with lymphomatoid papulosis. Read More

View Article and Full-Text PDF

Endoscopic features of colorectal lymphoma according to histological type.

JGH Open 2022 Apr 6;6(4):257-262. Epub 2022 Apr 6.

Endoscopy Division National Cancer Center Hospital Chuo City Tokyo Japan.

Background And Aim: This study aimed to investigate the relationship between the histological type of colorectal lymphoma and its endoscopic features.

Methods: We retrospectively analyzed patients with primary colorectal lymphoma who were diagnosed using colonoscopy and biopsy specimens at the National Cancer Center Hospital, Tokyo, Japan. The lesions were macroscopically classified into the following types via colonoscopy: polypoid, ulcerative, multiple lymphomatous polyposis, diffuse, and mixed. Read More

View Article and Full-Text PDF

MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia.

Leuk Res 2022 05 19;116:106841. Epub 2022 Apr 19.

University of New Hampshire, Department of Molecular, Cellular and Biomedical Sciences, Durham, NH 03824, USA. Electronic address:

Waldenström macroglobulinemia (WM) is a B cell lymphoma characterized by the overproduction of a monoclonal IgM antibody, a leading pathogenic feature of the disease. Current therapies are based on our knowledge at the signaling and genetic scale, but recent research has identified epigenetic dysregulation as one of the important dynamics in the biology of this disease. In this study, we found that Mixed-lineage leukemia 1 (MLL1) histone methyltransferase and its chromatin tethering partner Menin are upregulated in WM patients. Read More

View Article and Full-Text PDF

Painful ulcerations: the sole clinical sign of mixed cryoglobulinaemia secondary to marginal zone lymphoma.

BMJ Case Rep 2022 Apr 7;15(4). Epub 2022 Apr 7.

Dermatology, Box Hill Hospital, Box Hill, Victoria, Australia

A man in his 70s with background vascular disease presented with 7 months of painful non-resolving lower leg ulcers with eschar and petechiae, left lower ear lobe ulceration and dusky inflammation of the right ear. He demonstrated good bilateral pedal pulses and no peripheral oedema. No lymphadenopathy was palpated. Read More

View Article and Full-Text PDF

Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.

Transplant Cell Ther 2022 Jun 1;28(6):305.e1-305.e9. Epub 2022 Apr 1.

Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MFC-EDU, Tampa, FL 33612, United States.

The success of chimeric antigen receptor (CAR) T cell therapy in treating patients with relapsed/refractory hematologic malignancies is leading to a growing number of survivors treated with this regimen. To our knowledge, no previous studies have examined neurocognitive performance in adult CAR T cell therapy recipients, despite high rates of neurotoxicity and cytokine release syndrome (CRS) in the acute treatment period. This study examined changes in neurocognitive performance in the first year after CAR T cell therapy for non-Hodgkin lymphoma (NHL). Read More

View Article and Full-Text PDF

Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

Transplant Cell Ther 2022 Jun 11;28(6):294-302. Epub 2022 Mar 11.

Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, Birmingham, Alabama; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Chimeric antigen receptor (CAR) T cell therapy is a novel therapy for patients with relapsed or refractory hematologic malignancies. Most CAR T cell therapy recipients will experience clinical features of the immune effector cell-associated neurotoxicity syndrome (ICANS), a potentially life-threatening condition. Here we describe the clinical, biological, and radiological findings associated with ICANS in adults with hematologic malignancies treated with CAR T cell therapy, as well as the acute and long-term outcomes of ICANS. Read More

View Article and Full-Text PDF

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.

J Exp Clin Cancer Res 2022 Mar 14;41(1):97. Epub 2022 Mar 14.

University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.

Background: Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combination with rituximab yielded high objective response rates in patients with relapsed/refractory DLBCL in a phase I trial. Here, we report on a new bispecific and fully human fusion protein comprising the extracellular domains of SIRPα and 4-1BBL, termed DSP107, for the treatment of DLBCL. Read More

View Article and Full-Text PDF


Retina 2022 03;42(3):561-568

Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy; and.

Purpose: To investigate the frequency, risk factors, and functional prognosis of chorioretinal atrophy (CRA) in vitreoretinal lymphoma (VRL).

Methods: This was a retrospective cohort study of consecutive patients with vitreoretinal lymphoma. The demographic, clinical, and retinal features and the treatment modalities of each patient were collected. Read More

View Article and Full-Text PDF

Clinical Features and Surgical Treatment of Primary Pulmonary Lymphoma: A Retrospective Study.

Front Oncol 2022 3;12:779395. Epub 2022 Feb 3.

Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Background: Primary pulmonary lymphoma (PPL) is a rare clonal lymphoproliferative lung disease. The present study analyzes the clinical features, imaging data, pathologic characteristics, treatment, and prognosis of PPL patients, with the aim to discuss the appropriate diagnosis and therapy of PPL patients in thoracic surgery.

Methods: We performed a retrospective analysis on 36 patients with PPL confirmed by postoperative pathology between 2006 and 2020. Read More

View Article and Full-Text PDF
February 2022

A challenging case of lymphoproliferative disease in a cat.

Vet Clin Pathol 2022 Jun 18;51(2):263-268. Epub 2022 Feb 18.

Genefast, Forlì, Italy.

A 7-year-old male castrated Maine Coon cat presented with edema of the right hindlimb and a markedly enlarged right popliteal lymph node. A CBC showed a neutropenia of 1.5 × 10 /μL. Read More

View Article and Full-Text PDF

Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.

Oncogene 2022 03 28;41(11):1600-1609. Epub 2022 Jan 28.

Department of Immunology, Medical University of Warsaw, Warsaw, Poland.

The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-Lineage Leukemia (MLL) gene rearrangements (MLLr BCP-ALL) is still extremely poor. Inhibition of anti-apoptotic protein BCL-2 with venetoclax emerged as a promising strategy for this subtype of BCP-ALL, however, lack of sufficient responses in preclinical models and the possibility of developing resistance exclude using venetoclax as monotherapy. Herein, we aimed to uncover potential mechanisms responsible for limited venetoclax activity in MLLr BCP-ALL and to identify drugs that could be used in combination therapy. Read More

View Article and Full-Text PDF

A Rare Case of Tracheal Crystal-Storing Histiocytosis Associated with Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.

Int J Surg Pathol 2022 Jan 25:10668969221074615. Epub 2022 Jan 25.

Department of Pathology, Fukuoka University Hospital and School of Medicine, Jonan-ku, Fukuoka, Japan.

Crystal-storing histiocytosis (CSH) is a rare non-neoplastic histiocytic lesion with abnormal accumulation of immunoglobulin (Ig) light chain. CSH is associated with Ig overproduction by B-lymphoproliferative disorders (B-LPDs) or by persistent inflammatory diseases. Eighteen cases of pulmonary CSH have been reported. Read More

View Article and Full-Text PDF
January 2022

Composite Classic Hodgkin Lymphoma and Follicular Lymphoma: A Clinicopathologic Study of 22 Cases With Review of 27 Additional Cases in the Literature.

Am J Surg Pathol 2022 06 24;46(6):793-800. Epub 2022 Jan 24.

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.

Composite classic Hodgkin lymphoma and follicular lymphoma (CHLFL) is a rare and poorly characterized entity. Herein, we report the clinicopathologic features of 22 cases of CHLFL from 3 institutions and we assess 27 additional cases reported in the literature. In our cohort (n=22), patients with CHLFL had a median age of 61 years and an equal male to female incidence. Read More

View Article and Full-Text PDF

Cytopathological characteristics of angioimmunoblastic T-cell lymphoma diagnosed by fine needle aspiration.

Cytopathology 2022 Jul 28;33(4):499-504. Epub 2022 Jan 28.

Department of Hematology, Rheumatology The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.

Objective: To analyse the cytopathological features of fine needle aspiration (FNA) in angioimmunoblastic T-cell lymphoma (AITL) diagnostics.

Methods: Fine needle aspiration lymph node biopsy samples from 12 patients with AITL were collected at a single centre between January 2014 and December 2020. The clinical, cytological and histopathological characteristics were retrospectively analysed. Read More

View Article and Full-Text PDF

Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.

Am J Surg Pathol 2022 04;46(4):486-497

Department of Pathology.

Primary central nervous system lymphoma (PCNSL) of peripheral T-cell lineage (T-PCNSL) is rare, and its genetic and clinicopathologic features remain unclear. Here, we present 11 cases of T-PCNSL in immunocompetent individuals from a single institute, focusing on their genetic alterations. Seven cases were subject to targeted panel sequencing covering 120 lymphoma-related genes. Read More

View Article and Full-Text PDF

Clinical Outcomes of B Cell Acute Lymphoblastic Leukemia Patients Treated with Haploidentical Stem Cells Combined with Umbilical Cord Blood Transplantation.

Transplant Cell Ther 2022 03 22;28(3):173.e1-173.e6. Epub 2021 Dec 22.

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic address:

Clinical outcomes of hematopoietic stem cell transplantation (HSCT) using a haploidentical stem cell graft and an unrelated umbilical cord blood unit (haplo-cord HSCT) for the treatment of B cell acute lymphoblastic leukemia (B-ALL) remain unclear. This study was conducted to explore the clinical outcomes of haplo-cord HSCT in patients with B-ALL. A total of 112 B-ALL patients who underwent haplo-cord HSCT and 64 B-ALL patients who underwent haploidentical HSCT (haplo-HSCT) at our center between 2010 and 2020 were retrospectively included in this study, and clinical outcomes and prognostic factors were further analyzed. Read More

View Article and Full-Text PDF

Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana.

JCO Glob Oncol 2021 09;7:1620-1632

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Purpose: With intense HIV epidemics, southern African countries have a high burden of classic Hodgkin lymphoma (CHL) and non-Hodgkin lymphoma (NHL). However, suboptimal access to pathology resources limits subtype classification. We sought to assess the diagnostic accuracy of specimens classified as lymphoma and to determine association between discordant pathologic diagnosis and overall survival. Read More

View Article and Full-Text PDF
September 2021

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.

Viruses 2021 11 9;13(11). Epub 2021 Nov 9.

Clinical Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Extrahepatic manifestations are a feature of chronic hepatitis C virus (HCV) infection. In the course of chronic HCV infection, about 70% of patients have one or more extrahepatic manifestations. The latter are often the first and only clinical sign of infection. Read More

View Article and Full-Text PDF
November 2021

Vaccination History and Risk of Lymphoma and Its Major Subtypes.

Cancer Epidemiol Biomarkers Prev 2022 02 15;31(2):461-470. Epub 2021 Nov 15.

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Background: Vaccinations have been hypothesized to play a role in lymphoma etiology, but there are few studies, mixed results, and limited data on lymphoma subtypes. Herein, we investigate the association of vaccinations with risk of major lymphoma subtypes.

Methods: We studied 2,461 lymphoma cases and 2,253 controls enrolled from 2002 to 2014. Read More

View Article and Full-Text PDF
February 2022

Complement Factor H Gene Variant in a Patient with Thrombotic Microangiopathy on a Mixed Clinical Background.

Case Rep Nephrol 2021 25;2021:2519918. Epub 2021 Oct 25.

Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-754 Asahinachi-Dori, Niigata 951-8510, Japan.

We report the case of a patient with gene variant, who developed thrombotic microangiopathy on a mixed clinical background. A 79-year-old woman was transferred to Sanjo General Hospital for maintenance hemodialysis. She suffered from gastric non-Hodgkin lymphoma about two years ago and received chemotherapy and radiation therapy, leading to complete remission. Read More

View Article and Full-Text PDF
October 2021

Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes.

Clin Transl Sci 2022 03 29;15(3):680-690. Epub 2021 Nov 29.

Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China.

Previous exposure-response analyses for rituximab suggest that higher rituximab concentrations were associated with an improvement in efficacy, however, clinical studies investigating a higher rituximab dose had mixed results. To further explore the exposure-response relationship of rituximab, a prospective observational analysis was performed involving 121 newly diagnosed patients with diffuse large B-cell lymphoma treated with triweekly rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The trough concentration in the first cycle (C ) was significantly higher in patients achieving complete response (CR) compared with patients that did not achieve CR (22. Read More

View Article and Full-Text PDF